News Release

Semaglutide or tirzepatide and optic nerve and visual pathway disorders in type 2 diabetes

JAMA Network Open

Peer-Reviewed Publication

JAMA Network

About The Study: In this study of patients with type 2 diabetes who had no prior eye disorders, patients prescribed semaglutide or tirzepatide had an increased risk of nonarteritic anterior ischemic optic neuropathy and other optic nerve disorders, although the overall risk was low. These findings highlight the need for close monitoring of these conditions.

Corresponding Author: To contact the corresponding author, Rong Xu, PhD, email rxx@case.edu.

To access the embargoed study: Visit our For The Media website at this link https://media.jamanetwork.com/

(doi:10.1001/jamanetworkopen.2025.26327)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

#  #  #

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time http://jamanetwork.com/journals/jamanetworkopen/fullarticle/10.1001/jamanetworkopen.2025.26327?utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_term=081125

About JAMA Network Open: JAMA Network Open is an online-only open access general medical journal from the JAMA Network. On weekdays, the journal publishes peer-reviewed clinical research and commentary in more than 40 medical and health subject areas. Every article is free online from the day of publication. 


Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.